Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Reports First Quarter 2018 Financial Results
Key Highlights: Top-line results from Phase III study with RHB-104 for Crohn’s disease (MAP US study) expected in approximately 3 months Top-line results from confirmatory Phase III study with TALICIA ® for H. pylori infection (ERADICATE Hp2 study) expected Q4/2018 Net revenues of $2.4 million and ...
View HTML
Toggle Summary RedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohn’s Disease
Top-line results from the Phase III study with RHB-104 for Crohn’s disease are expected to be announced in approximately three months   Worldwide sales of Crohn’s disease therapies are estimated to exceed $10 billion in 2018   Top-line results from the confirmatory Phase III study with TALICIA ® ...
View HTML
Toggle Summary RedHill Biopharma Announces Enrollment of 300th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
Approximately 70% of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA ® for H. pylori infection (ERADICATE Hp2) RedHill expects to complete enrollment in Q3/2018 and announce top-line results in Q4/2018   The study is expected to ...
View HTML
Toggle Summary RedHill Biopharma to Host First Quarter 2018 Financial Results Conference Call on May 8, 2018
TEL-AVIV, Israel and RALEIGH, N.C. , May 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma Provides Semi-Annual Business Update
TEL-AVIV, Israel and RALEIGH, N.C. , April 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma Announces Two Oral Presentations on BEKINDA® 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting
TEL-AVIV, Israel and RALEIGH, N.C. , March 27, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA® for IBS-D
TEL-AVIV, Israel and RALEIGH, N.C. , March 26, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma to Present at H.C. Wainwright Annual Global Life Sciences Conference
TEL-AVIV, Israel and RALEIGH, N.C. , March 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma Announces Poster Presentation on New Potential Therapeutic Applications of RHB-107 at the AACR 2018 Annual Meeting
Data from non-clinical studies indicated that WX-UK1, the active metabolite of RHB-107 (formerly MESUPRON), is a potent and specific inhibitor of five human serine proteases, suggesting new potential therapeutic applications in oncology and inflammatory digestive diseases TEL-AVIV , Israel and ...
View HTML
Toggle Summary RedHill Biopharma Provides Fourth Quarter and Full-Year 2017 Investor Update
Key Highlights: Top-line results from the Phase III study with RHB-104 for Crohn’s disease expected in mid-2018 Top-line results from the confirmatory Phase III study with TALICIA ®  for H. pylori infection expected in the second half of 2018 Net revenues of $2 million and gross profit of $1 . ...
View HTML